AI Startups
Chai Discovery nabs $400M Series C as AI-designed antibodies reach Big Pharma
Chai Discovery secures $400M to scale AI-driven drug discovery, tripling its valuation to $3.8 billion.
Chai Discovery Inc., a company that develops artificial intelligence models to predict interactions between biochemical molecules, today announced it has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion. Index Ventures led the round alongside...
S
SiliconANGLE
Source
SiliconANGLERead the full story at SiliconANGLE

AI Analysis
Generated insight by OnAirToday AI
Chai Discovery's massive funding round underscores the accelerating convergence of generative AI and biotechnology in drug discovery. By streamlining the prediction of complex molecular interactions, these models are dramatically shortening the timeline for bringing life-saving antibody treatments to market.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Filed under:AI Startups
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.